1.58
Erasca Inc stock is traded at $1.58, with a volume of 395.76K.
It is down -1.25% in the last 24 hours and down -9.20% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.60
Open:
$1.59
24h Volume:
395.76K
Relative Volume:
0.35
Market Cap:
$448.20M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.9268
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+8.22%
1M Performance:
-9.20%
6M Performance:
+22.48%
1Y Performance:
-41.91%
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ERAS
Erasca Inc
|
1.58 | 453.87M | 0 | -125.04M | -122.99M | -0.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-26-25 | Initiated | Raymond James | Outperform |
Nov-18-24 | Initiated | Jefferies | Buy |
Mar-11-24 | Initiated | CapitalOne | Overweight |
Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
Oct-11-23 | Initiated | H.C. Wainwright | Buy |
Mar-30-23 | Initiated | Mizuho | Buy |
Feb-24-23 | Initiated | Goldman | Buy |
Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
What the charts say about Erasca Inc. todayIPO Watch & Consistent Growth Stock Picks - Newser
Automated trading signals detected on Erasca Inc.Weekly Trade Report & Smart Investment Allocation Tips - Newser
When is the best time to exit Erasca Inc.Market Growth Report & Risk Managed Trade Strategies - Newser
Published on: 2025-08-27 10:28:36 - Newser
Risk adjusted return profile for Erasca Inc. analyzed2025 Dividend Review & Free Expert Verified Stock Movement Alerts - Newser
Will Erasca Inc. stock go up soonJuly 2025 Highlights & Real-Time Buy Signal Notifications - Newser
Erasca Inc. stock volume spike explainedJuly 2025 Closing Moves & Short-Term Trading Alerts - Newser
Using flow based indicators on Erasca Inc.July 2025 Technicals & Fast Moving Trade Plans - Newser
Why Erasca Inc. stock attracts strong analyst attentionShort Setup & Weekly Chart Analysis and Guides - Newser
Is Erasca Inc. stock ready for a breakoutCEO Change & AI Based Buy and Sell Signals - Newser
Relative strength of Erasca Inc. in sector analysis2025 Winners & Losers & Low Risk Entry Point Guides - Newser
Advanced analytics toolkit walkthrough for Erasca Inc.2025 Price Momentum & Consistent Growth Stock Picks - Newser
Technical analysis overview for Erasca Inc. stockJuly 2025 Highlights & Safe Swing Trade Setup Alerts - Newser
Technical Charts Suggest Momentum Shift in Erasca Inc.2025 Technical Patterns & Technical Confirmation Alerts - Newser
Quant Funds Rotate Into Erasca Inc. Stock getLinesFromResByArray error: size == 0 - kangso.co.kr
How to escape a deep drawdown in Erasca Inc.2025 Fundamental Recap & AI Driven Stock Price Forecasts - Newser
Published on: 2025-08-26 13:22:53 - beatles.ru
Multi factor analysis applied to Erasca Inc.July 2025 Summary & Proven Capital Preservation Methods - Newser
Market reaction to Erasca Inc.’s recent newsJuly 2025 Gainers & Stepwise Trade Signal Implementation - Newser
Should I buy Erasca Inc. stock nowSwing Trade & Capital Protection Trading Alerts - classian.co.kr
What’s the profit margin of Erasca Inc.Market Sentiment Report & Technical Pattern Based Buy Signals - theviewers.co.kr
Candlestick signals on Erasca Inc. stock todayJuly 2025 Drop Watch & Reliable Price Breakout Alerts - Newser
Erasca Inc. Attempts Reversal From Key Support2025 Growth vs Value & Long-Term Investment Growth Plans - kangso.co.kr
Why is Erasca Inc. stock going upJuly 2025 Short Interest & Risk Managed Investment Signals - sundaytimes.kr
Can Erasca Inc. be recession proofTrade Analysis Summary & Daily Entry Point Trade Alerts - theviewers.co.kr
Will Erasca Inc. Bounce From 52 Week Low2025 Fundamental Recap & Community Trade Idea Sharing - kangso.co.kr
Published on: 2025-08-20 02:52:23 - Newser
Is it time to cut losses on Erasca Inc.Market Performance Recap & Smart Swing Trading Alerts - Newser
Is Erasca Inc. stock entering bullish territoryDay Trade & Real-Time Stock Price Movement Reports - Newser
How to track smart money flows in Erasca Inc.July 2025 Earnings & Trade Opportunity Analysis - Newser
Erasca Inc (ERAS Stock: A Sea of Opportunity - investchronicle.com
Erasca (NASDAQ:ERAS) Receives Equal Weight Rating from Morgan Stanley - Defense World
Should you wait for a breakout in Erasca Inc.2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Traders Watching For Reversal Pattern in Erasca Inc.2025 Performance Recap & Low Drawdown Trading Strategies - sundaytimes.kr
Erasca's Strategic Reprioritization and Pipeline Delays: A Cautionary Tale for Biotech Investors - AInvest
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):